Investors Purchase Large Volume of Call Options on BioNTech (NASDAQ:BNTX)

BioNTech SE (NASDAQ:BNTX) was the recipient of some unusual options trading on Monday. Traders purchased 1,989 call options on the company. This is an increase of approximately 31% compared to the typical daily volume of 1,519 call options.

BioNTech Trading Up 0.7 %

NASDAQ:BNTX opened at $93.35 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.26 and a current ratio of 9.43. The business’s 50-day simple moving average is $90.54 and its 200 day simple moving average is $95.99. The stock has a market cap of $22.19 billion, a price-to-earnings ratio of 22.66 and a beta of 0.25. BioNTech has a one year low of $85.21 and a one year high of $125.83.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Wednesday, March 20th. The company reported $2.05 EPS for the quarter, missing the consensus estimate of $2.64 by ($0.59). BioNTech had a return on equity of 4.60% and a net margin of 24.26%. The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $2.04 billion. As a group, sell-side analysts predict that BioNTech will post -1.74 earnings per share for the current fiscal year.

Institutional Trading of BioNTech

A number of institutional investors and hedge funds have recently modified their holdings of the business. Baillie Gifford & Co. grew its holdings in BioNTech by 1.0% in the 4th quarter. Baillie Gifford & Co. now owns 8,689,182 shares of the company’s stock worth $917,056,000 after buying an additional 86,343 shares in the last quarter. Primecap Management Co. CA grew its holdings in BioNTech by 2.8% during the fourth quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock worth $502,735,000 after acquiring an additional 131,490 shares during the period. Harding Loevner LP bought a new stake in shares of BioNTech in the 4th quarter worth approximately $410,984,000. Flossbach Von Storch AG grew its position in BioNTech by 1.0% in the fourth quarter. Flossbach Von Storch AG now owns 3,548,660 shares of the company’s stock worth $374,526,000 after buying an additional 35,445 shares during the last quarter. Finally, Capital World Investors grew its position in BioNTech by 1.5% in the fourth quarter. Capital World Investors now owns 938,747 shares of the company’s stock worth $99,075,000 after buying an additional 14,027 shares during the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on BNTX. BMO Capital Markets cut their target price on shares of BioNTech from $127.00 to $123.00 and set an “outperform” rating for the company in a research note on Thursday, March 21st. Canaccord Genuity Group reiterated a “buy” rating and issued a $171.00 price target on shares of BioNTech in a report on Thursday, March 21st. UBS Group lowered their price objective on BioNTech from $110.00 to $101.00 and set a “neutral” rating for the company in a research report on Wednesday, March 27th. HC Wainwright reiterated a “buy” rating and set a $107.00 price objective on shares of BioNTech in a report on Wednesday, April 17th. Finally, The Goldman Sachs Group decreased their price target on shares of BioNTech from $113.00 to $100.00 and set a “neutral” rating on the stock in a report on Wednesday, February 28th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $120.40.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.